HMRlignan Questions and Answers

Q.What are lignans?


Lignans are phyto-nutrients, a class of plant compounds beneficial to human health. They are one three main groups of plant compounds classified as phytoestrogen – the other two being isoflavonoids and coumestans. Lignans are a normal part of a healthy diet and widely distributed in foods and plants in small amounts. The most common dietary sources of lignans are whole grains, seeds, nuts, legumes, fruits, and vegetables. The predominant plant lignans of dietary importance are matairesinol, hydroxymatairesinol (HMR), secoisolariciresinol, and pinoresinol.

Q.Where does HMRlignan™ come from?


HMRlignan™ (7-hydroxymatairesinol) is sourced from the Norway spruce (Picea abies), which is abundant in the Nordic countries. The Norway spruce is used extensively in paper manufacturing, one of the primary industries in Finland and has led to a strong national industrial and academic interest in the study of wood chemistry. Finnish researchers discovered that the knot wood (which is discarded during processing for paper) is high in 7-hydroxymatairesinol (7-HMR).

Hormos Medical Corporation of Turku, Finland, has played the lead role in the development of HMRlignan™. The proprietary extraction method yields a high concentration of 7-HMR making HMRlignan™ one of the most potent lignan supplements currently available.

Q.How does HMRlignan™ differ from flax and other commercially available lignans?


As HMRlignan™ is not in a food matrix it has a superior bioavailability. Other lignans, such as flax, are glycosides – bound to sugar molecules – that must first be cleaved in the body before they can be metabolized into the target molecule enterolactone (ENL). HMRlignan™ is a pure lignan in the aglycone form (not bound to sugars) and upon arrival in a healthy intestinal tract, is more efficiently transformed into ENL. HMRlignan™ is the industry’s first and only direct ENL precursor.

Q.What is the recommended daily dose of HMRlignan™?


To increase and maintain healthy levels of enterolactone (ENL), pharmacokinetic data suggests that a daily of at least 36 mg/day.1 In an 8-week study with postmenopausal women, both 36 mg and 72 mg/day doses effectively raised ENL levels compared to baseline with a greater effect at the 72 mg/day dose.1 In the same study, hot flashes were significantly reduced at both 4 weeks (55% reduction; p = 0.009) and 8 weeks (50% reduction; p = 0.025) in women taking 72 mg/day of HMRlignan.

1. Udani JK, Brown DJ, Tan MOC, Hardy M. Pharmacokinetics and bioavailability of plant lignin 7-hydroxymatairesinol and effects on serum enterolactone and clinical symptoms in postmenopausal women: A single-blinded, parallel, dose-comparison study. J Amer Coll Nutr 2013;32:428-35.